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LETTER TO THE EDITOR
The Editor
Journal of Investigative Dermatology
962 Park Avenue
New York, N. Y.
Sir:
In the article entitled "Untoward Reactions to Patch Tests" by Ervin Epstein
appearing in the April issue, there is a discussion of the danger of performing
patch tests with nicotine solutions. The author goes on to say "Rostenberg and
Sulzberger recommend that tests be carried out with a 5% aqueous solution of
nicotine sulphate. On the face of it, the technical error in applying such a con-
centrated solution is obvious." My reason for writing is that I think that the
author's warning should be heeded, but even more important is that a distinction
be made between nicotine as the free alkaloid and as one of its salts. There has
been much toxicologic and pharmacologic investigation which show that free
nicotine is readily absorbed through the intact skin, whereas its salts (practically
all the work has been done with the sulphate) do not penetrate in any significant
amounts. It is stated that 4 mgms. or less of the free alkaloid can cause serious
symptoms in an unhabituated individual. This would mean that if 0.10 cc. of a
40% nicotine solution were used for patch testing and only 10% of this were ab-
sorbed the individual would receive approximately 4 mgms. The concentration
recommended by Rostenberg and Sulzberger is correct inasmuch as at that dose it
is not a primary irritant but is sufficiently strong to detect the hypersensitive in-
dividual and yet will not cause systemic reactions on a pharmacologic basis.
Sincerely yours,
ADOLPH ROSTENBERG, JR., M.D.
Senior Medical Officer
Received May 9, 1942.
REPLY TO THE FOREGOING REMARKS BY DR ROSTENBERG
ReceiYed June 18, 1942
I do not feel that an answer is necessary as the letter does not disagree with my
article. Rather, it has amplified and clarified one of the statements made in this
paper. I wish to thank Dr. Rostenberg for his interest and for the valuable addi-
tion that he has made to my understanding of the subject.
ERvIN EPSTEIN, M.D.
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